NEW YORK (GenomeWeb News) – Kettering Health Network, a collection of six hospitals in Ohio, plans to use Diatherix Laboratories' PCR-based molecular diagnostic tests to identify patients with H1N1 influenza and hospital-acquired and infectious diseases, Diatherix said.
Kettering Medical Center will be the first hospital in the network to use the target-enriched multiplex PCR (TEM-PCR) system, which enables physicians to simultaneously test for H1N1 flu, methicillin-resistant staphylococcus aureus, clostridium difficile, and other infectious diseases.
Kettering expects that by adopting the TEM-PCR test, which takes around six hours to produce results, it will save money at all of its hospitals. Specifically, it projects a savings of around $225,000 per year on MRSA infections at KMC alone, and that it will save expenses on other infectious diseases at all of the five hospitals in the network.
One extra cost associated with hospital-acquired infections is caused by the necessity to isolate infected patients.
"Every time someone enters the room of an isolated patient, he must gown up and glove up and sometimes use special masks," Carol Quinter, lab technical director and coordinator of clinical studies at KMC, said in a statement. "All of this is very time-consuming, expensive, and underutilizes the hospital's bed capacity," she said, adding that technologies that reduce such isolation expenses would be "invaluable."
Diatherix is located at the HudsonAlpha Institute for Biotechnology in Huntsville, Ala., and it runs an independent CLIA-certified lab that provides molecular multiplex diagnostic services.
Financial terms of the agreement were not released.